Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer

By Zent O.   Banzhoff A.   Hilbert A.K.   Meriste S.   Sluzewski W.   Wittermann C.  

Vaccine, Vol. 21, Iss. 25, 2003-09 ,pp. : 3584-3592

Elsevier

Access to resources Recommend Favorite

Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination

By Boulianne N.   De Serres G.   Duval B.   Ratnam S.   Ward B.J.   Joly J.R.  

Vaccine, Vol. 13, Iss. 16, 1995-11 ,pp. : 1611-1616

Elsevier

Access to resources Recommend Favorite

Vaccination against tick-borne encephalitis (TBE): influence of simultaneous application of TBE immunoglobulin on seroconversion and rate of adverse events

By Hedenstrom M.v.   Heberle U.   Theobald K.  

Vaccine, Vol. 13, Iss. 8, 1995-06 ,pp. : 759-762

Elsevier

Access to resources Recommend Favorite

Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination

By Totos G.   Gizaris V.   Papaevangelou G.  

Vaccine, Vol. 15, Iss. 11, 1997-08 ,pp. : 1252-1253

Elsevier

Access to resources Recommend Favorite

Hepatitis B vaccine immunoresponsiveness in adolescents: a revaccination proposal after primary vaccination

By Minana J.S.   Ganuza M.G.   Millan P.F.   Fernandez M.P.  

Vaccine, Vol. 14, Iss. 2, 1996-02 ,pp. : 103-106

Elsevier

Access to resources Recommend Favorite